Man Group plc bought a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 150,854 shares of the medical instruments supplier’s stock, valued at approximately $673,000.
A number of other institutional investors and hedge funds have also bought and sold shares of OSUR. Quadrature Capital Ltd bought a new position in OraSure Technologies in the 4th quarter valued at about $28,000. Legal & General Group Plc acquired a new position in shares of OraSure Technologies in the second quarter valued at approximately $30,000. Prudential Financial Inc. acquired a new position in shares of OraSure Technologies in the second quarter valued at approximately $31,000. Diversify Wealth Management LLC bought a new position in shares of OraSure Technologies during the first quarter worth approximately $36,000. Finally, Diversify Advisory Services LLC acquired a new stake in OraSure Technologies during the 2nd quarter worth approximately $47,000. Institutional investors and hedge funds own 93.50% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on OSUR shares. Weiss Ratings restated a “sell (d-)” rating on shares of OraSure Technologies in a research note on Tuesday. Wall Street Zen raised OraSure Technologies from a “sell” rating to a “hold” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $3.00.
OraSure Technologies Stock Down 0.8%
OSUR stock opened at $3.58 on Friday. OraSure Technologies, Inc. has a 12 month low of $2.08 and a 12 month high of $4.58. The firm has a market cap of $246.91 million, a P/E ratio of -5.19 and a beta of 0.99. The company’s 50-day moving average price is $4.00 and its two-hundred day moving average price is $3.56.
About OraSure Technologies
OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.
The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.
See Also
- Five stocks we like better than OraSure Technologies
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
